PFIZER INC
Financial highlights
| Metric | FY 12/31/25 | FY 12/31/24 | FY 12/31/23 | FY 12/31/22 | FY 12/31/21 |
|---|---|---|---|---|---|
| Income Statement | |||||
| Revenue | $62.6 | $63.6 | $59.6 | $101.2 | $81.3 |
| Net income | $7.8 | $8.0 | $2.1 | $31.4 | $22.0 |
| Cash Flow Statement | |||||
| Free cash flow | $9.1 | $9.8 | $4.8 | $26.0 | $29.9 |
| Dividends | $9.8 | $9.5 | $9.2 | $9.0 | $8.7 |
| Share repurchases | $0.0 | $0.0 | $0.0 | $2.0 | $0.0 |
Shares outstanding 5.7B · Free float 100.0%
Annual filing data through FY ended December 31, 2025; float as of September 17, 2026.
Earnings
Other Coverage
September 28, 2026
QBook
Stronger demand supports expansion as pricing diverges
September 23, 2026
Drug Pipeline
Abivax, Merck and Teva–Sanofi pursue the next wave of colitis therapies
September 23, 2026
Drug Pipeline
Lilly and Novo set the backdrop for a changing obesity pipeline
September 23, 2026
Drug Pipeline
Pfizer’s Velsipity brings an oral option to ulcerative colitis
September 23, 2026
Drug Pipeline
Pfizer’s oral GLP-1 program ended with danuglipron’s discontinuation
August 14, 2026
Industry Earnings Roundup
Healthcare Earnings: Demand Surges, Costs Bite Back